On the New York Post's opinion page, Sally Pipes of Pacific Research Institute writes about two campuses with menegitis outbreaks and how current vaccines given don't prevent the disease from spreading. However, a 20 year old vaccine available in Europe, Canada and Australia is still being delayed by the FDA.
Twenty years in the making, the vaccine has undergone numerous clinical trials involving nearly 8,000 infants, children, adolescents and adults. US health officials, alarmed by the outbreak, have taken the unprecedented step of importing the drug as part of an emergency vaccination campaign at Princeton.
Yet Bexsero is still awaiting approval by the Food and Drug Administration. A combination of excessive caution and regulatory inertia has left thousands of Americans vulnerable to this dangerous disease.
A strong dose of caution when it comes to approving new treatments may seem like a virtue. But as the students and families affected by these outbreaks know, excess caution can have grave consequences.